Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis

Charles H. Chesnut, David J. Baylink, Karen Sisom, Wil B. Nelp, Bernard A. Roos

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Calcitonin (CT) deficiency has been suggested as an etiologic factor in postmenopausal osteoporosis (PM-OP). Basal immunoreactive calcitonin (iCT) was measured with a sensitive radioimmunoassay (RIA) in 62 PM-OP women with compressin fractures (CF) and in 28 normal age-matched women. Mean iCT values in the two groups were not significantly different (43.5 and 45.1 pg/ml, p > 0.10). In the 62 PM-OP females, no significant correlation was noted between basal plasma iCT levels and (1) age; (2) severity of disease as assessed by number of CF; (3) serum calcium, phosphorus, alkaline phosphatase, and immunoreactive parathyroid hormone; and (4) total bone mass as assessed by neutron activation analysis determinations of total body calcium (TBC). In 20 PM-OP patients treated for 24 mo with 100 Medical Research Council (MRC) units daily of synthetic salmon CT, no correlation was observed between basal plasma iCT and response of bone mass (TBC) to therapy. These data suggest that basal CT is not decreased in women with PM-OP, and that the level of circulating CT does not influence therapeutic changes in bone mass during CT therapy. CT is probably not a major etiologic or pathogenetic factor in PM-OP.

Original languageEnglish
Pages (from-to)559-562
Number of pages4
JournalMetabolism
Volume29
Issue number6
DOIs
StatePublished - Jan 1 1980
Externally publishedYes

Fingerprint

Postmenopausal Osteoporosis
Calcitonin
salmon calcitonin
Calcium
Bone and Bones
Neutron Activation Analysis
Parathyroid Hormone
Phosphorus
Radioimmunoassay
Alkaline Phosphatase
Biomedical Research
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Chesnut, C. H., Baylink, D. J., Sisom, K., Nelp, W. B., & Roos, B. A. (1980). Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis. Metabolism, 29(6), 559-562. https://doi.org/10.1016/0026-0495(80)90082-7

Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis. / Chesnut, Charles H.; Baylink, David J.; Sisom, Karen; Nelp, Wil B.; Roos, Bernard A.

In: Metabolism, Vol. 29, No. 6, 01.01.1980, p. 559-562.

Research output: Contribution to journalArticle

Chesnut, CH, Baylink, DJ, Sisom, K, Nelp, WB & Roos, BA 1980, 'Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis', Metabolism, vol. 29, no. 6, pp. 559-562. https://doi.org/10.1016/0026-0495(80)90082-7
Chesnut, Charles H. ; Baylink, David J. ; Sisom, Karen ; Nelp, Wil B. ; Roos, Bernard A. / Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis. In: Metabolism. 1980 ; Vol. 29, No. 6. pp. 559-562.
@article{809f9ca46a82464da93b1fa72923c7ab,
title = "Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis",
abstract = "Calcitonin (CT) deficiency has been suggested as an etiologic factor in postmenopausal osteoporosis (PM-OP). Basal immunoreactive calcitonin (iCT) was measured with a sensitive radioimmunoassay (RIA) in 62 PM-OP women with compressin fractures (CF) and in 28 normal age-matched women. Mean iCT values in the two groups were not significantly different (43.5 and 45.1 pg/ml, p > 0.10). In the 62 PM-OP females, no significant correlation was noted between basal plasma iCT levels and (1) age; (2) severity of disease as assessed by number of CF; (3) serum calcium, phosphorus, alkaline phosphatase, and immunoreactive parathyroid hormone; and (4) total bone mass as assessed by neutron activation analysis determinations of total body calcium (TBC). In 20 PM-OP patients treated for 24 mo with 100 Medical Research Council (MRC) units daily of synthetic salmon CT, no correlation was observed between basal plasma iCT and response of bone mass (TBC) to therapy. These data suggest that basal CT is not decreased in women with PM-OP, and that the level of circulating CT does not influence therapeutic changes in bone mass during CT therapy. CT is probably not a major etiologic or pathogenetic factor in PM-OP.",
author = "Chesnut, {Charles H.} and Baylink, {David J.} and Karen Sisom and Nelp, {Wil B.} and Roos, {Bernard A.}",
year = "1980",
month = "1",
day = "1",
doi = "10.1016/0026-0495(80)90082-7",
language = "English",
volume = "29",
pages = "559--562",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis

AU - Chesnut, Charles H.

AU - Baylink, David J.

AU - Sisom, Karen

AU - Nelp, Wil B.

AU - Roos, Bernard A.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - Calcitonin (CT) deficiency has been suggested as an etiologic factor in postmenopausal osteoporosis (PM-OP). Basal immunoreactive calcitonin (iCT) was measured with a sensitive radioimmunoassay (RIA) in 62 PM-OP women with compressin fractures (CF) and in 28 normal age-matched women. Mean iCT values in the two groups were not significantly different (43.5 and 45.1 pg/ml, p > 0.10). In the 62 PM-OP females, no significant correlation was noted between basal plasma iCT levels and (1) age; (2) severity of disease as assessed by number of CF; (3) serum calcium, phosphorus, alkaline phosphatase, and immunoreactive parathyroid hormone; and (4) total bone mass as assessed by neutron activation analysis determinations of total body calcium (TBC). In 20 PM-OP patients treated for 24 mo with 100 Medical Research Council (MRC) units daily of synthetic salmon CT, no correlation was observed between basal plasma iCT and response of bone mass (TBC) to therapy. These data suggest that basal CT is not decreased in women with PM-OP, and that the level of circulating CT does not influence therapeutic changes in bone mass during CT therapy. CT is probably not a major etiologic or pathogenetic factor in PM-OP.

AB - Calcitonin (CT) deficiency has been suggested as an etiologic factor in postmenopausal osteoporosis (PM-OP). Basal immunoreactive calcitonin (iCT) was measured with a sensitive radioimmunoassay (RIA) in 62 PM-OP women with compressin fractures (CF) and in 28 normal age-matched women. Mean iCT values in the two groups were not significantly different (43.5 and 45.1 pg/ml, p > 0.10). In the 62 PM-OP females, no significant correlation was noted between basal plasma iCT levels and (1) age; (2) severity of disease as assessed by number of CF; (3) serum calcium, phosphorus, alkaline phosphatase, and immunoreactive parathyroid hormone; and (4) total bone mass as assessed by neutron activation analysis determinations of total body calcium (TBC). In 20 PM-OP patients treated for 24 mo with 100 Medical Research Council (MRC) units daily of synthetic salmon CT, no correlation was observed between basal plasma iCT and response of bone mass (TBC) to therapy. These data suggest that basal CT is not decreased in women with PM-OP, and that the level of circulating CT does not influence therapeutic changes in bone mass during CT therapy. CT is probably not a major etiologic or pathogenetic factor in PM-OP.

UR - http://www.scopus.com/inward/record.url?scp=0018870112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018870112&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(80)90082-7

DO - 10.1016/0026-0495(80)90082-7

M3 - Article

C2 - 7382823

AN - SCOPUS:0018870112

VL - 29

SP - 559

EP - 562

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 6

ER -